Arthur Franken
Direktor/Vorstandsmitglied bei Moximed, Inc.
Ursprung des Netzwerks ersten Grades von Arthur Franken
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Gilde Healthcare Partners BV
 Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge.
22
| Subsidiary | Investment Managers | 22 |
Moximed, Inc.
 Moximed, Inc. Medical SpecialtiesHealth Technology Moximed, Inc. develops minimally invasive, joint sparing solutions for patients with knee osteoarthritis. Its Osteoarthritis treatment can minimize joint pain, restore normal activity levels, and slow down disease progression. The company was founded by Anton G. Clifford in 2006 and is headquartered in Hayward, CA.
13
| Holding Company | Medical Specialties | 13 |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation.
8
| Holding Company | Biotechnology | 8 |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.
7
| Holding Company | Pharmaceuticals: Generic | 7 |
Noema Pharma AG
 Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland.
7
| Holding Company | Biotechnology | 7 |
Calypso Biotech BV
 Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands.
6
| Holding Company | Biotechnology | 6 |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.
4
| Subsidiary | Medical Specialties | 4 |
Calypso Biotech SA
 Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany.
4
| Subsidiary | Pharmaceuticals: Major | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Arthur Franken
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Analyst | |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures, Inc. ( Medimmune Ventures) is a venture capital firm founded in 2002 by Ron Laufer, Wayne Hockmeyer and David Mott . The firm is headquartered in Gaithersburg, Maryland. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
Ivantis, Inc.
 Ivantis, Inc. Medical SpecialtiesHealth Technology Ivantis, Inc. develops technology to treat ophthalmic diseases. The firm develops solutions for glaucoma and offers an intracanalicular scaffold or implantable device that relieves high intraocular pressures in patients. It provides its solutions for use in clinical trials to ophthalmology specialists. Ivantis was founded in 2007 and is headquartered in Irvine, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
Nuvaira, Inc.
 Nuvaira, Inc. Electronic Equipment/InstrumentsElectronic Technology Nuvaira, Inc. develops medical devices for treating lung diseases. It works on a novel catheter-based system that has the potential to improve lung function, exercise capacity and quality of life for patients with chronic obstructive pulmonary disease. The company was founded by Steven Dimmer and Martin L. Mayse in 2008 and is headquartered in Plymouth, MN. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member Director/Board Member | |
Earlens Corp.
 Earlens Corp. Medical SpecialtiesHealth Technology Earlens Corp. develops medical devices. It offers EarLens Contact Hearing Device that uses light to transmit sound. Its earlens contact hearing device two components: a tympanic membrane transducer, which is nonsurgically placed deep in the ear canal on the eardrum, and a light-based behind-the-ear sound processor placed at the base of the ear canal. The company was founded in 1999 by Rodney C. Perkins and is headquartered in Menlo Park, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
Gilde Investment Management BV
 Gilde Investment Management BV Investment ManagersFinance Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht. | Investment Managers | Director/Board Member Investment Committee Member Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Corporate Officer/Principal Undergraduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Investment Managers | Private Equity Analyst Chief Investment Officer | |
| Yale University | College/University | Graduate Degree Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
| Erasmus University Rotterdam | College/University | Graduate Degree Graduate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
| Southeast BIO | Director/Board Member Director/Board Member | ||
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Founder Private Equity Investor Private Equity Investor | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
Medlumics SL
 Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal Private Equity Analyst | |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Director/Board Member | |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder Private Equity Investor | |
Capella Bioscience Ltd.
 Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inhibitaxin Ltd.
 Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder Founder | |
| Creabilis SA | Chief Executive Officer Director/Board Member | ||
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder | |
Vertex Ventures HC
 Vertex Ventures HC Investment ManagersFinance Vertex Ventures HC (Vertex Ventures) is a venture capital subsidiary of Vertex Venture Holdings Ltd founded in 2014. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
Synexa Life Sciences BV
 Synexa Life Sciences BV BiotechnologyHealth Technology Synexa Life Sciences BV is a Dutch company that specializes in Biomarker and Bioanalysis Research Services. The company is based in Leiden, Netherlands. The company has expertise in designing and delivering biomarker strategies for biopharma clients. and has subsidiaries in Finland. The company was founded in 2003 by Justin Devine, Patrick Bouic, Paul O'Riordan. The CEO is Emile Lens. | Biotechnology | Director/Board Member Director/Board Member | |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Director/Board Member Director/Board Member | |
Rappta Therapeutics Oy
 Rappta Therapeutics Oy BiotechnologyHealth Technology Rappta Therapeutics Oy operates as a biopharmaceutical company. It develops anti-cancer drugs activating protein phosphatase 2A. The company was founded by Goutham Narla and Mikko Lauri Sampsa Mannerkoski on March 20, 2019 and is headquartered in Helsinki, Finland. | Biotechnology | Director/Board Member Chairman | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Director/Board Member Director/Board Member |
Statistik
International
| Vereinigte Staaten | 18 |
| Vereinigtes Königreich | 12 |
| Niederlande | 8 |
| Schweiz | 4 |
| Spanien | 4 |
Sektoral
| Health Technology | 28 |
| Finance | 9 |
| Consumer Services | 8 |
| Commercial Services | 3 |
| Electronic Technology | 2 |
Operativ
| Director/Board Member | 480 |
| Corporate Officer/Principal | 104 |
| Chairman | 72 |
| Independent Dir/Board Member | 68 |
| Private Equity Investor | 64 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Antoine Papiernik | 48 |
| Ed Mathers Mathers | 47 |
| Joshua Makower | 37 |
| Francesco de Rubertis | 36 |
| Eliot Forster | 35 |
| Hank Plain | 33 |
| Catherine Moukheibir | 29 |
| Brigitte Smith | 28 |
| Mike Gutch | 24 |
| Alexandre LeBeaut | 22 |
| Steven Powell | 22 |
| Fiona MacLaughlin | 22 |
| Kevin Johnson | 22 |
| Jeff Jonas | 21 |
- Börse
- Insiders
- Arthur Franken
- Unternehmensverbindungen
